Sustainable Endotoxin Testing: Chromogenic Assay with Recombinant Cascade Reagents
Catalog Number
No. |
Description |
Sensitivity EU/ml |
RCR100TA |
BETMAT™ rCR Endotoxin Assay Kit（Recombinant Cascade Reagents Chromogenic Method), 100 Tests/Kit |
0.005-5EU/ml |
RCR100TB |
0.001-10EU/ml |
|
RCR300TA |
BETMAT™ rCR Endotoxin Assay Kit（Recombinant Cascade Reagents Chromogenic Method), 300 Tests/Kit |
0.005-5EU/ml |
RCR300TB |
0.001-10EU/ml |
|
MRCR100T |
BETMAT™ mrCR Endotoxin Assay Kit for Small Volume Samples (Recombinant Cascade Reagents Chromogenic Method), 100Tests/Kit |
0.005-5EU/ml |
Products Features
The Recombinant Cascade Reagent (RCR) represents a significant advancement in bacterial endotoxin testing, serving as a sustainable and hightory expectations while maintaining robust analytical performance.
A key advantage of RCR lies in its sustainable and entirely animal-free production process. By utilizing recombinant technology, it eliminates dependency on horseshoe crab blood, thereby supporting conservation efforts and promoting animal welfare without compromising reagent supply. Furthermore, the recombinant cascade—comprising recombinant Factor C, Factor B, and proclotting enzyme—ensures a reaction mechanism that closely mirrors that of native LAL, resulting in a high degree of correlation with conventional endotoxin test methods.
Another critical feature is the enhanced specificity of RCR. Unlike native LAL reagents, it is not activated by (1→3)-β-D-glucans, which are known to cause false-positive results in certain samples. This attribute significantly improves test accuracy and reliability in complex pharmaceutical matrices. In addition, the use of RCR is supported by emerging pharmacopeial standards, such as the proposed USP <86> chapter titled “Bacterial Endotoxins Test Using Recombinant Reagents,” facilitating its adoption in regulated laboratory environments.
Finally, the applicability of RCR has been demonstrated across a range of real-world pharmaceutical products, where it has exhibited excellent sample compatibility and produced results comparable to those obtained with traditional LAL-based methods. This proven performance, combined with its ethical and regulatory advantages, positions RCR as a modern and responsible choice for endotoxin testing in the pharmaceutical industry.ly specific recombinant alternative to traditional Limulus Amoebocyte Lysate (LAL). Its development aligns with modern ethical and regula.
Recombinant Factor C Assay applications as follows
Pharmaceutical products: It can be used for the detection of bacterial endotoxins in various pharmaceutical products, including raw materials, in-process products, and final products, such as injection solutions (e.g., 5% glucose injection, potassium chloride injection), antibiotics (e.g., erythromycin injection), and biological products (e.g., stem cell materials).
Nuclear medicine samples: Ensure the safety of nuclear medicine samples by detecting bacterial endotoxins to prevent potential adverse reactions caused by endotoxins during clinical use.
Dialysis samples: In the field of dialysis, it is used to detect endotoxins in dialysis solutions and related products to ensure the quality and safety of dialysis treatment.
Cell and gene therapy materials: For cell and gene therapy products, rCR can be used to detect endotoxins in cell culture media, vectors, and other materials to avoid interference of endotoxins with the therapeutic effect and safety.
Pharmaceutical water systems: Monitor the quality of water used in pharmaceutical production, such as purified water and water for injection, to ensure that the water does not contain excessive bacterial endotoxins.
Cleaning validations: In the process of cleaning pharmaceutical equipment and facilities, rCR can be used to detect whether there are residual bacterial endotoxins to ensure the cleanliness of the equipment and the safety of subsequent product production.
Medical devices: Used for the detection of bacterial endotoxins in medical devices, such as syringes, catheters, and surgical instruments, to ensure that the devices are free from endotoxin contamination and will not cause harm to the human body after use.
Compounded products: In compounding pharmacies, rCR can be used to detect the endotoxin content in compounded drugs to ensure the quality and safety of compounded products.
Technical Information
The BET recombinant cascade reagent (rCR) is an advanced, non-animal-derived alternative to traditional Limulus amebocyte lysate (LAL) for bacterial endotoxin testing (BET). Here’s a detailed technical breakdown:
1. Composition & Mechanism
Recombinant Enzymes: rCR mimics the natural LAL cascade using three key recombinant proteins:
Recombinant Factor C (rFC): Initiates the cascade by binding to endotoxins.
Recombinant Factor B (rFB): Amplifies the signal through enzymatic activation.
Recombinant Proclotting Enzyme (rPCE): Catalyzes the final step, cleaving a chromogenic or turbidimetric substrate to generate a measurable signal .
Signal Generation:
Chromogenic Assays: Release of a colored product (e.g., p-nitroaniline) allows kinetic or endpoint detection.
Turbidimetric Assays: Formation of a clot increases turbidity, measured spectrophotometrically.
Specificity: Unlike LAL, rCR lacks Factor G, eliminating false-positive reactions caused by (1→3)-β-D-glucans (e.g., fungal contaminants) .
2. Validation & Regulatory Compliance
USP Chapter <86> Approval (effective May 2025): Permits rCR for endotoxin testing under the same compendial standards as LAL. Validation follows USP <1225> and ICH Q2(R2) guidelines, including linearity, accuracy, precision, and robustness .
Global Acceptance: Compliant with EP (via LAL equivalence) and USP requirements, with ongoing harmonization efforts.
3. Technical Performance
Detection Range: Typically 0.005–5 EU/mL (0.001 - 10EU/mL), matching LAL sensitivity for most applications .
Reaction Time:
a. Kinetic Chromogenic: 60 minutes .
b. Endpoint: 60 minutes.
Interference Control: Built-in resistance to glucans and other non-endotoxin pyrogens. Matrix effects (e.g., extreme pH, detergents) are minimized through formulation optimization and user-specific validation .
Lot-to-Lot Consistency: Recombinant production ensures reduced variability compared to LAL, which relies on harvested horseshoe crab hemolymph .
4. Storage & Handling
Stability: Shelf life of 24 months at 2–8°C .
Convenience: Single-vial format eliminates complex mixing (e.g., Charles River’s pre-loaded cartridges).
Compatible with existing LAL equipment (e.g., Endoscan-V, Pyrosmart) without hardware modifications .
5. Advantages Over LAL
Sustainability: Eliminates reliance on horseshoe crab blood, aligning with the 3Rs principles (Replacement, Reduction, Refinement) .
Supply Chain Security: Recombinant production ensures consistent availability, avoiding seasonal or geographic shortages .
Simplified Workflow: Fewer steps and reduced hands-on time (e.g., Charles River’s cartridges minimize contamination risk) .
Cost Efficiency: Lower long-term costs due to reduced reagent waste, simplified validation, and elimination of glucan blockers .
6. Limitations & Considerations
Matrix Complexity: Some samples (e.g., vaccines with adjuvants) may require additional validation to confirm absence of interference .
Initial Investment: Higher upfront costs for validation packages, though offset by operational savings .
Regulatory Transition: While USP <86> permits rCR, some regions may require additional documentation for specific products .
7. Future Directions
Automation: Integration with robotic systems for high-throughput testing.
Expanded Validation: Ongoing studies to support rCR use in complex matrices like gene therapies and oral formulations.
Regulatory Harmonization: Alignment with EP and USP guidelines for broader adoption .